Travere Therapeutics Stock EBITDA
| TVTX Stock | USD 19.06 0.88 4.84% |
Travere Therapeutics fundamentals help investors to digest information that contributes to Travere Therapeutics' financial success or failures. It also enables traders to predict the movement of Travere Stock. The fundamental analysis module provides a way to measure Travere Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Travere Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -326.2 M | -309.9 M |
Travere | EBITDA |
Travere Therapeutics Company EBITDA Analysis
Travere Therapeutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Travere Therapeutics EBITDA | (326.25 M) |
Most of Travere Therapeutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Travere Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Travere EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Travere Therapeutics is extremely important. It helps to project a fair market value of Travere Stock properly, considering its historical fundamentals such as EBITDA. Since Travere Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Travere Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Travere Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Travere Ebitda
According to the company disclosure, Travere Therapeutics reported earnings before interest,tax, depreciation and amortization of (326.25 Million). This is 137.18% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The ebitda for all United States stocks is 108.37% higher than that of the company.
Travere EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Travere Therapeutics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Travere Therapeutics could also be used in its relative valuation, which is a method of valuing Travere Therapeutics by comparing valuation metrics of similar companies.Travere Therapeutics is currently under evaluation in ebitda category among its peers.
Travere Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Travere Therapeutics from analyzing Travere Therapeutics' financial statements. These drivers represent accounts that assess Travere Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Travere Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 601.2M | 1.3B | 1.9B | 1.3B | 667.7M | 572.6M | |
| Enterprise Value | 743.7M | 1.4B | 2.0B | 1.7B | 1.0B | 646.3M |
Travere Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Travere Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Travere Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Travere Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Travere Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Travere Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Travere Therapeutics' value.| Shares | D. E. Shaw & Co Lp | 2024-09-30 | 1.8 M | Finepoint Capital Lp | 2024-06-30 | 1.8 M | Geode Capital Management, Llc | 2024-09-30 | 1.7 M | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 1.6 M | Assenagon Asset Management Sa | 2024-09-30 | 1.4 M | Kynam Capital Management, Lp | 2024-09-30 | 1.4 M | Balyasny Asset Management Llc | 2024-09-30 | 1.3 M | Woodline Partners Lp | 2024-06-30 | 1.3 M | Emerald Mutual Fund Advisers Trust | 2024-09-30 | 1.2 M | Armistice Capital, Llc | 2024-09-30 | 7.6 M | Blackrock Inc | 2024-06-30 | 7.6 M |
Travere Fundamentals
| Return On Equity | -2.8 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (1.73) % | ||||
| Operating Margin | (0.89) % | ||||
| Current Valuation | 1.71 B | ||||
| Shares Outstanding | 87.03 M | ||||
| Shares Owned By Insiders | 0.65 % | ||||
| Shares Owned By Institutions | 98.59 % | ||||
| Number Of Shares Shorted | 7.99 M | ||||
| Price To Book | 76.10 X | ||||
| Price To Sales | 7.78 X | ||||
| Revenue | 145.24 M | ||||
| Gross Profit | (31.35 M) | ||||
| EBITDA | (326.25 M) | ||||
| Net Income | (376.33 M) | ||||
| Cash And Equivalents | 553.17 M | ||||
| Cash Per Share | 8.65 X | ||||
| Total Debt | 404.78 M | ||||
| Debt To Equity | 2.60 % | ||||
| Current Ratio | 4.71 X | ||||
| Book Value Per Share | (0.39) X | ||||
| Cash Flow From Operations | (280.02 M) | ||||
| Short Ratio | 3.92 X | ||||
| Earnings Per Share | (4.52) X | ||||
| Price To Earnings To Growth | (0.02) X | ||||
| Target Price | 26.94 | ||||
| Number Of Employees | 380 | ||||
| Beta | 0.7 | ||||
| Market Capitalization | 1.58 B | ||||
| Total Asset | 788.91 M | ||||
| Retained Earnings | (1.13 B) | ||||
| Working Capital | 438.87 M | ||||
| Net Asset | 788.91 M |
About Travere Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Travere Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Travere Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Travere Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Travere Stock Analysis
When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.